70 related articles for article (PubMed ID: 17159658)
1. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
Karlström O; Josephson F; Sönnerborg A
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658
[TBL] [Abstract][Full Text] [Related]
2. Protease inhibitor levels in hair strongly predict virologic response to treatment.
Gandhi M; Ameli N; Bacchetti P; Gange SJ; Anastos K; Levine A; Hyman CL; Cohen M; Young M; Huang Y; Greenblatt RM;
AIDS; 2009 Feb; 23(4):471-8. PubMed ID: 19165084
[TBL] [Abstract][Full Text] [Related]
3. Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
Hong Y; Kowalski KG; Zhang J; Zhu L; Horga M; Bertz R; Pfister M; Roy A
Antimicrob Agents Chemother; 2011 Dec; 55(12):5746-52. PubMed ID: 21930880
[TBL] [Abstract][Full Text] [Related]
4. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.
McCance-Katz EF; Moody DE; Morse GD; Ma Q; DiFrancesco R; Friedland G; Pade P; Rainey PM
Drug Alcohol Depend; 2007 Dec; 91(2-3):269-78. PubMed ID: 17643869
[TBL] [Abstract][Full Text] [Related]
5. Atazanavir: its role in HIV treatment.
Wood R
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):785-96. PubMed ID: 19053892
[TBL] [Abstract][Full Text] [Related]
6. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.
Kiser JJ; Rutstein RM; Samson P; Graham B; Aldrovandi G; Mofenson LM; Smith E; Schnittman S; Fenton T; Brundage RC; Fletcher CV
AIDS; 2011 Jul; 25(12):1489-96. PubMed ID: 21610486
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
Foissac F; Blanche S; Dollfus C; Hirt D; Firtion G; Laurent C; Treluyer JM; Urien S
Br J Clin Pharmacol; 2011 Dec; 72(6):940-7. PubMed ID: 21649692
[TBL] [Abstract][Full Text] [Related]
8. Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
Moyle G; Else L; Jackson A; Back D; Yapa MH; Seymour N; Ringner-Nackter L; Karolia Z; Gazzard B; Boffito M
Antimicrob Agents Chemother; 2013 Aug; 57(8):3640-4. PubMed ID: 23689708
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
Mollan K; Daar ES; Sax PE; Balamane M; Collier AC; Fischl MA; Lalama CM; Bosch RJ; Tierney C; Katzenstein D;
J Infect Dis; 2012 Dec; 206(12):1920-30. PubMed ID: 23148287
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin.
Gausi K; Mugerwa H; Siccardi M; Montanha MC; Lamorde M; Wiesner L; D'Avolio A; McIlleron H; Wilkins E; De Nicolò A; Maartens G; Khoo S; Kityo C; Denti P; Waitt C
Clin Infect Dis; 2024 May; 78(5):1246-1255. PubMed ID: 37982585
[TBL] [Abstract][Full Text] [Related]
11. Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.
Antoniou T; Szadkowski L; Walmsley S; Cooper C; Burchell AN; Bayoumi AM; Montaner JS; Loutfy M; Klein MB; Machouf N; Tsoukas C; Wong A; Hogg RS; Raboud J;
BMC Infect Dis; 2017 Apr; 17(1):266. PubMed ID: 28399819
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database.
Boettiger DC; Nguyen VK; Durier N; Bui HV; Heng Sim BL; Azwa I; Law M; Ruxrungtham K
J Acquir Immune Defic Syndr; 2015 Feb; 68(2):186-95. PubMed ID: 25590271
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment.
Chawana TD; Nhachi CFB; Nathoo K; Ngara B; Okochi H; Louie A; Kuncze K; Katzenstein D; Metcalfe J; Gandhi M;
J Acquir Immune Defic Syndr; 2021 Oct; 88(2):181-185. PubMed ID: 34117162
[TBL] [Abstract][Full Text] [Related]
14. Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.
Dolling DI; Dunn DT; Sutherland KA; Pillay D; Mbisa JL; Parry CM; Post FA; Sabin CA; Cane PA; ;
J Antimicrob Chemother; 2013 Oct; 68(10):2339-43. PubMed ID: 23711895
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.
Cain LE; Caniglia EC; Phillips A; Olson A; Muga R; Pérez-Hoyos S; Abgrall S; Costagliola D; Rubio R; Jarrín I; Bucher H; Fehr J; van Sighem A; Reiss P; Dabis F; Vandenhende MA; Logan R; Robins J; Sterne JAC; Justice A; Tate J; Touloumi G; Paparizos V; Esteve A; Casabona J; Seng R; Meyer L; Jose S; Sabin C; Hernán MA;
Medicine (Baltimore); 2016 Oct; 95(41):e5133. PubMed ID: 27741139
[TBL] [Abstract][Full Text] [Related]
16. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.
Puligujja P; McMillan J; Kendrick L; Li T; Balkundi S; Smith N; Veerubhotla RS; Edagwa BJ; Kabanov AV; Bronich T; Gendelman HE; Liu XM
Nanomedicine; 2013 Nov; 9(8):1263-73. PubMed ID: 23680933
[TBL] [Abstract][Full Text] [Related]
17. Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment.
Chawana TD; Gandhi M; Nathoo K; Ngara B; Louie A; Horng H; Katzenstein D; Metcalfe J; Nhachi CFB;
J Acquir Immune Defic Syndr; 2017 Sep; 76(1):55-59. PubMed ID: 28520618
[TBL] [Abstract][Full Text] [Related]
18. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
Siccardi M; D'Avolio A; Baietto L; Gibbons S; Sciandra M; Colucci D; Bonora S; Khoo S; Back DJ; Di Perri G; Owen A
Clin Infect Dis; 2008 Nov; 47(9):1222-5. PubMed ID: 18831695
[TBL] [Abstract][Full Text] [Related]
19. A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents.
Ngara B; Zvada S; Chawana TD; Stray-Pedersen B; Nhachi CFB; Rusakaniko S
BMC Pharmacol Toxicol; 2020 Aug; 21(1):58. PubMed ID: 32746923
[TBL] [Abstract][Full Text] [Related]
20. Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
Venuto CS; Lim J; Messing S; Hunt PW; McComsey GA; Morse GD
Antivir Ther; 2018; 23(4):345-351. PubMed ID: 29171837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
